Agenus Inc. (AGEN) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 7, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the AGEN SEC filings page.
Agenus Inc. (AGEN) reported $132.7M in revenue over the twelve months to Jun 30, 2026, up 30.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Agenus sharply reduced losses by cutting spending, but negative equity and weak cash generation still define its financing model.
The near-break-even net result in FY2025 did not mean the business became cash-generative: net loss fell to$3M , yet operating cash flow remained-$77M . Because free cash flow nearly matched operating cash flow while capital spending was negligible, the earnings improvement has not translated into internally funded operations.
Gross margin stayed near 99% in FY2024 and FY2025, so the improvement was not driven by cheaper production. Instead, the operating loss narrowed from
FY2025 liabilities were more than twice assets, and equity remained negative at
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Agenus Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Agenus Inc. held $3.0M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $77.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Agenus Inc. scores 2/100 among other emerging companies.
Agenus Inc. had 38M shares outstanding at the end of fiscal year 2025, against 25M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Agenus Inc. scores 95/100 among other emerging companies.
Agenus Inc. spent $79.3M on research and development in fiscal year 2025, which was 59.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Agenus Inc. scores 82/100 among other emerging companies.
Agenus Inc. reported revenue of $114.2M in fiscal year 2025, against $103.5M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Agenus Inc. scores 25/100 among other emerging companies.
Agenus Inc.'s operations used $77.2M of cash in fiscal year 2025, against $158.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Agenus Inc. scores 77/100 among other emerging companies.
Agenus Inc.'s cash, cash equivalents and investments came to $3.0M at the end of fiscal year 2025, against $497.9M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Agenus Inc. scores 2/100 among other emerging companies.
Agenus Inc. scores -13.94, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($272.8M) relative to total liabilities ($497.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Agenus Inc. passes 4 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
Agenus Inc. reported a net loss of $3.1M while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Agenus Inc. reported an operating loss of $20.2M against $55.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Agenus Inc. generated $34.5M in revenue in Q2 2026. This represents an increase of 34.4% from the same quarter a year earlier. Against the prior quarter it is up 2.3%.
Agenus Inc.'s EBITDA was $11.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 187.2% from the same quarter a year earlier. Against the prior quarter it is down 24.5%.
Agenus Inc. reported -$567K in net income in Q2 2026. This represents an increase of 98.1% from the same quarter a year earlier. Against the prior quarter it is down 101.4%.
Agenus Inc. earned -$0.01 per diluted share (EPS) in Q2 2026. Against the prior quarter it is down 101.0%.
Cash & Balance Sheet
Agenus Inc. recorded an outflow of $31.2M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents a decrease of 54.3% from the same quarter a year earlier. Against the prior quarter it is up 13.2%.
Agenus Inc. held $18.7M in cash against $30.1M in long-term debt as of Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Agenus Inc.'s gross margin was 100.0% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.9 percentage points from the same quarter a year earlier. It is unchanged from the prior quarter.
Agenus Inc.'s operating margin was 32.7% in Q2 2026, reflecting core business profitability. This is up 97.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 11.9 percentage points.
Agenus Inc.'s net profit margin was -1.6% in Q2 2026, showing the share of revenue converted to profit. No change is given against Q2 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for Q2 2026.
Capital Allocation
Agenus Inc. invested $14.8M in research and development in Q2 2026. This represents a decrease of 44.7% from the same quarter a year earlier. Against the prior quarter it is up 24.8%.
Agenus Inc. reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier.
Not reported for Q2 2026.
AGEN Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $34.5M+34.4% | $33.7M+40.2% | $34.2M+27.5% | $30.2M+20.4% | $25.7M+9.3% | $24.1M-14.1% | $26.8M-68.0% | $25.1M+3.3% |
| Cost of Revenue | $0-100.0% | $0-100.0% | $0-100.0% | $642K+339.7% | $243K+111.3% | $137K+28.0% | $118K-54.6% | $146K-51.8% |
| Gross Profit | $34.5M+35.6% | $33.7M+41.0% | $34.2M+28.0% | $29.6M+18.5% | $25.4M+8.8% | $23.9M-14.2% | $26.7M-68.0% | $25.0M+4.0% |
| R&D Expenses | $14.8M-44.7% | $11.8M-45.1% | $7.5M-77.8% | $23.6M-42.5% | $26.7M-27.4% | $21.5M-51.0% | $33.8M-49.4% | $41.1M-20.2% |
| SG&A Expenses | $8.5M-45.4% | $6.9M-56.4% | $12.3M-41.3% | $10.9M-37.1% | $15.5M-7.7% | $15.7M-6.7% | $20.9M-1.2% | $17.3M-8.6% |
| Operating Income | $11.3M+167.6% | $15.1M+213.1% | $14.4M+155.6% | -$4.5M+85.6% | -$16.7M+44.7% | -$13.3M+59.5% | -$25.9M-516.4% | -$31.5M+32.0% |
| EBITDA | $11.8M+187.2% | $15.6M+254.7% | $15.0M+166.2% | -$1.5M+94.6% | -$13.5M+49.5% | -$10.1M+65.7% | -$22.6M-2363.6% | -$28.2M+35.3% |
| Interest Expense | $15.4M+15.1% | $14.7M+13.1% | $16.0M-24.0% | $13.2M-64.0% | $13.3M-58.7% | $13.0M-57.1% | $21.1M-57.9% | $36.7M+97.2% |
| Net Income | -$567K+98.1% | $39.2M+248.7% | -$10.6M+77.3% | $63.9M+195.1% | -$30.0M+45.2% | -$26.4M+58.4% | -$46.8M+3.7% | -$67.2M-4.2% |
| EPS (Basic) | -$0.01+99.0% | $1.03+200.0% | -$0.37+80.9% | $2.00+164.9% | -$1.00+60.3% | -$1.03+66.1% | -$1.94+16.4% | -$3.08+6.4% |
| EPS (Diluted) | -$0.01 | $1.02 | -$0.37+80.9% | $1.94 | -$1.00+60.3% | -$1.03+66.1% | -$1.94+16.4% | -$3.08 |
| Diluted Shares (Avg) | 41M | 38M | N/A | 33M | 28M+33.5% | 24M+20.1% | N/A | 22M |
Not reported in any period shown, so not listed: Income Tax.
AGEN Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $172.7M-6.8% | $186.5M-6.9% | $226.8M+0.2% | $233.9M-1.9% | $185.2M-36.7% | $200.2M-22.0% | $226.3M-27.9% | $238.5M-28.9% |
| Current Assets | $78.8M+490.8% | $95.3M+311.8% | $133.4M+192.8% | $133.9M+167.1% | $13.3M-86.7% | $23.1M-61.7% | $45.6M-59.5% | $50.2M-60.1% |
| Cash & Equivalents | $18.7M+96.5% | $35.0M+89.3% | $3.0M-92.6% | $3.5M-92.3% | $9.5M-89.8% | $18.5M-65.0% | $40.4M-46.9% | $44.8M-57.9% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Receivable | $14.7M+1976.9% | $6.6M+1753.7% | $1.8M+349.9% | $538K+159.9% | $709K-1.4% | $354K-25.6% | $407K-98.4% | $207K-79.9% |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $24.1M0.0% | $24.1M0.0% | $24.1M0.0% | $24.1M-2.4% | $24.1M-2.7% | $24.1M-2.5% | $24.1M-2.6% | $24.7M+0.1% |
| Total Liabilities | $371.8M-31.1% | $407.7M-24.8% | $497.9M-9.9% | $508.0M-4.3% | $539.8M+1.1% | $542.0M+18.4% | $552.7M+16.5% | $530.8M+14.3% |
| Current Liabilities | $231.8M-1.2% | $249.2M+19.7% | $323.5M+46.1% | $287.1M+6.1% | $234.6M-13.3% | $208.3M-18.6% | $221.4M-13.5% | $270.6M+36.4% |
| Non-Current Liabilities | $139.9M-54.2% | $158.4M-52.5% | $174.4M-47.3% | $220.9M-15.1% | $305.3M+16.0% | $333.7M+65.2% | $331.3M+51.7% | $260.2M-2.3% |
| Long-Term Debt | $30.1M+29.9% | $30.2M-8.1% | N/A | $23.6M | $23.2M | $32.8M | $30.5M+138.7% | $0-100.0% |
| Total Equity | -$199.1M+43.9% | -$221.2M+35.3% | -$271.1M+16.9% | -$274.1M+6.2% | -$354.6M-46.9% | -$341.8M-69.7% | -$326.4M-103.6% | -$292.3M-126.4% |
| Retained Earnings | -$2.1B+4.1% | -$2.1B+2.9% | -$2.2B0.0% | -$2.2B-1.6% | -$2.2B-8.0% | -$2.2B-9.4% | -$2.2B-11.6% | -$2.1B-11.9% |
Not reported in any period shown, so not listed: Inventory.
AGEN Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$31.2M-54.3% | -$36.0M-40.3% | -$16.6M+42.0% | -$14.7M+72.3% | -$20.2M+47.0% | -$25.6M+32.9% | -$28.7M+29.1% | -$53.3M+18.3% |
| Depreciation & Amortization | $517K-83.7% | $583K-81.8% | $597K-81.7% | $3.0M-9.4% | $3.2M-5.8% | $3.2M-5.1% | $3.3M-37.3% | $3.3M+17.3% |
| Stock-Based Compensation | $3.3M-5.3% | $1.1M-68.5% | N/A | $2.8M-69.7% | $3.4M-63.0% | $3.5M-16.1% | N/A | $9.3M+67.6% |
| Capital Expenditures | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% | $1K-99.8% | $5K-85.7% | $73K-67.3% | $7K-99.8% |
| Free Cash Flow | -$31.2M-54.3% | -$36.0M-40.3% | -$16.6M+42.1% | -$14.7M+72.4% | -$20.2M+47.7% | -$25.6M+33.0% | -$28.7M+29.3% | -$53.3M+22.4% |
| Investing Cash Flow | $267K-5.0% | $69.0M+120868.4% | $780K+3814.3% | $76K+35.7% | $281K+218.6% | $57K-75.1% | -$21K-100.7% | $56K-99.5% |
| Financing Cash Flow | $14.7M+34.2% | -$993K-127.6% | $15.4M-36.9% | $6.7M+46.7% | $10.9M-86.2% | $3.6M-75.8% | $24.4M+233.2% | $4.6M-74.7% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
AGEN Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%+0.9pp | 100.0%+0.6pp | 100.0%+0.4pp | 97.9%-1.5pp | 99.1%-0.5pp | 99.4%-0.2pp | 99.6%-0.1pp | 99.4%+0.7pp |
| Operating Margin | 32.7%+97.8pp | 44.6%+99.9pp | 42.1%+138.6pp | -15.0% | -65.0% | -55.3% | -96.5%-91.5pp | -125.4% |
| Net Margin | -1.6% | 116.2% | -31.0% | 211.4% | -116.8% | -109.6% | -174.4% | -267.7% |
| Return on Assets | -0.3%+15.9pp | 21.0%+34.2pp | -4.7%+16.0pp | 27.3%+55.5pp | -16.2%+2.5pp | -13.2%+11.6pp | -20.7%-5.2pp | -28.2%-8.9pp |
| Current Ratio | 0.34+0.3x | 0.38+0.3x | 0.41+0.2x | 0.47+0.3x | 0.06-0.3x | 0.11-0.1x | 0.21-0.2x | 0.19-0.4x |
| Asset Turnover | 0.20+0.1x | 0.18+0.1x | 0.150.0x | 0.130.0x | 0.14+0.1x | 0.120.0x | 0.12-0.1x | 0.110.0x |
| FCF Margin | -90.4%-11.7pp | -106.6% | -48.6% | -48.7% | -78.7% | -106.5% | -107.0% | -212.3% |
Not reported in any period shown, so not listed: Return on Equity, Debt-to-Equity.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$271.1M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.41), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Agenus Inc. AGEN | FY2025 | $114.2M | -$3.1M | -2.7% | $272.8M | 47/100 |
| Alpha Cognition Inc. ACOG | FY2025 | $10.2M | -$20.7M | N/A | $178.4M | 34/100 |
| Greenwich LifeSciences, Inc. GLSI | FY2025 | N/A | -$19.4M | N/A | $213.6M | — |
| Coherus Oncology, Inc. CHRS | FY2025 | $42.2M | $168.0M | N/A | $153.0M | 61/100 |
| Nkarta, Inc. NKTX | FY2025 | $0 | -$104.1M | N/A | $128.9M | — |
| Avalo Therapeutics, Inc. AVTX | FY2025 | $59K | -$78.3M | N/A | $604.4M | — |
Where Agenus Inc. Ranks
Frequently Asked Questions
What is Agenus Inc.'s annual revenue?
Agenus Inc. (AGEN) reported $114.2M in total revenue for fiscal year 2025. This represents a 10.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Agenus Inc.'s revenue growing?
Agenus Inc. (AGEN) revenue grew by 10.4% year-over-year, from $103.5M to $114.2M in fiscal year 2025.
Is Agenus Inc. profitable?
No, Agenus Inc. (AGEN) reported a net income of -$3.1M in fiscal year 2025, with a net profit margin of -2.7%.
What is Agenus Inc.'s EBITDA?
Agenus Inc. (AGEN) had EBITDA of -$10.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Agenus Inc. have?
As of fiscal year 2025, Agenus Inc. (AGEN) had $3.0M in cash and equivalents against $0 in long-term debt.
What is Agenus Inc.'s gross margin?
Agenus Inc. (AGEN) had a gross margin of 99.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Agenus Inc.'s operating margin?
Agenus Inc. (AGEN) had an operating margin of -17.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Agenus Inc.'s net profit margin?
Agenus Inc. (AGEN) had a net profit margin of -2.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Agenus Inc.'s free cash flow?
Agenus Inc. (AGEN) recorded an outflow of $77.2M in free cash flow during fiscal year 2025. This represents a 51.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Agenus Inc.'s operating cash flow?
Agenus Inc. (AGEN) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Agenus Inc.'s total assets?
Agenus Inc. (AGEN) had $226.8M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Agenus Inc.'s capital expenditures?
Agenus Inc. (AGEN) invested $6K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Agenus Inc. spend on research and development?
Agenus Inc. (AGEN) invested $79.3M in research and development during fiscal year 2025.
What is Agenus Inc.'s current ratio?
Agenus Inc. (AGEN) had a current ratio of 0.41 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Agenus Inc.'s return on assets (ROA)?
Agenus Inc. (AGEN) had a return on assets of -1.4% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Agenus Inc.'s P/E ratio?
Agenus Inc. (AGEN) trades at 3.0x earnings, its market capitalization divided by net income of $91.9M net income, trailing 12 months to June 30, 2026. The market capitalization is $272.8M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Agenus Inc.'s price-to-sales ratio?
Agenus Inc. (AGEN) trades at 2.1x sales, its market capitalization divided by revenue of $132.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $272.8M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Agenus Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Agenus Inc. (AGEN) held $3.0M in cash, cash equivalents and investments, and reported an operating cash outflow of $77.2M over that year. Dividing the one by the other, the reported balance equals about 0 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Agenus Inc.'s debt-to-equity ratio negative or not reported?
Agenus Inc. (AGEN) has negative shareholder equity of -$271.1M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Agenus Inc.'s Altman Z-Score?
Agenus Inc. (AGEN) has an Altman Z-Score of -13.94, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Agenus Inc.'s Piotroski F-Score?
Agenus Inc. (AGEN) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Agenus Inc.'s earnings high quality?
Agenus Inc. (AGEN) reported a net loss of $3.1M while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Agenus Inc. cover its interest payments?
Agenus Inc. (AGEN) reported an operating loss of $20.2M against $55.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Agenus Inc.?
Agenus Inc. (AGEN) scores 47 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.